GM602 / Genervon - LARVOL DELTA

High-throughput Sequencing Reveals N6-methyladenosine-modified LncRNAs as Potential Biomarkers in Mice with Liver Fibrosis. (PubMed, Curr Gene Ther) - "This study revealed the unique m6A methylation pattern of lncRNAs in LF mice, suggesting that the m6A methylation modification of lncRNAs is related to the occurrence and development of LF."

Journal • Preclinical • Fibrosis • Hepatology • Immunology • Liver Cirrhosis • H19

GAP-PD-Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease (clinicaltrials.gov) - P2a; N=6; Completed; Sponsor: Genervon Biopharmaceuticals, LLC; Recruiting ➔ Completed; Trial primary completion date: Dec 2013 ➔ Jul 2014

Trial completion • Trial primary completion date • Biosimilar • Parkinson's Disease